Mundipharma Of Japan To Develop, Market Cancer Drug
This article was originally published in PharmAsia News
Japan's Mundipharma, which normally licenses its drug development and marketing to other drug makers, plans to do develop another company's drug. BioCryst Pharmaceuticals' forodesine HCL compound for treating T-cell lymphoma received orphan status from Japan's Health Ministry and Mundipharma licensed the drug. The Japanese firm expects to begin trials this fall and establish a sales division to market the drug in Japan and Europe on its own. Other drug makers, including Purdue Pharma of the United States, are associated with Mundipharma in the venture. (Click here for more - a subscription may be required
You may also be interested in...
White House and HHS are increasing pressure on FDA Commissioner Hahn to clear Pfizer and Moderna’s COVID-19 vaccines as soon as possible – potentially skirting the advisory committee process. The move is leaving a last-minute political stain on a regulatory process the FDA fought hard to keep science-based and could foster a new wave of vaccine hesitancy amongst the American public.
Two physicians experienced in agency affairs and operations, former commissioner David Kessler and former principal deputy commissioner Joshua Sharfstein, are reportedly finalists to head Biden’s FDA.
Operation Warp Speed will hold back initial shipments to ensure two-dose regimens can be completed; 15 December is ‘chalk’ target date for emergency authorization of Pfizer vaccine, OWS’ Gustave Perna says, calling it only a projection that does not impinge on FDA authority. Sending only half shipments also eases burden on cold shortage capacity at state and local level, he says.